Does GLP-1 suppress its own basal secretion?

References

• Elahi D, Hershlopf RJ, Muller DC, et al. Feedback inhibition of insulin secretion by insulin: relation to the hyperinsulinemia of obesity. N Eng J Med 1982;308:1196–202 ( Regul Pept 1995;58:149–56)
   Web of Science ®Google Scholar
• Brunicardi FC, Gingerich RL, Andersen DK. Selective effects of arterial insulin on islet cell secretion in the isolated perfused human pancreas. Surg Forum 1990;41:198–200
   Google Scholar
• Drucker D. Glucagon-like peptides. Diabetes 1998;47:159–69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239–46
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612–19
   PubMed Web of Science ®Google Scholar
• FDA. FDA Approves New Drug Treatment for Type 2 Diabetes. U.S. Department of Health & Human Services, 2009
   Google Scholar
• Kim BJ, Carlson OD, Jang HJ, et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab 2005;90:6665–71
   PubMed Web of Science ®Google Scholar
• Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin- mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002;87:3768–73
   PubMed Web of Science ®Google Scholar
• Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9-36) Amide, Cleavage Product of GLP-1 (7-36) Amide, Is a Glucoregulatory Peptide. Obesity (Silver Spring) 2008;16:1501–9
   PubMed Web of Science ®Google Scholar
• Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002;87:1282–90
   PubMed Web of Science ®Google Scholar
• Hansen L, Hartmann B, Bisgaard T, et al. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000;278:E1010–18
   PubMed Web of Science ®Google Scholar
• Marco J, Hedo JA, Villaneuva ML. Inhibition of intestinal glucagon-like immunoreactivity (GLI) secretion by somatostatin in man. J Clin Endocrinol Metab 1977;44:695–8
   PubMed Web of Science ®Google Scholar
• Martin PA, Faulkner A. Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep. J Endocrinol 1996;151:107–12
   PubMed Web of Science ®Google Scholar
• Naslund E, Bogefors J, Skogar S, et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999;277:R910–916
   PubMed Web of Science ®Google Scholar
• Tofit-Nielsen M-B, Masbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999;22:1137–43
   PubMed Web of Science ®Google Scholar
• Salehi M, Prigeon RL, D'Alessio DA. Gastric bypass surgery enhances glucagon-like peptide-1-stimulated postprandial insulin secretion in humans. Diabetes 2011;60:2308–14
   PubMed Web of Science ®Google Scholar
• Standeven KF, Hess K, Carter AM, et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes 2011;35:1031–40
   PubMed Web of Science ®Google Scholar
• Palmboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia 2005;48:1882–90
   PubMed Web of Science ®Google Scholar
• Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept 1995;58:149–56
   PubMed Web of Science ®Google Scholar
• Bak MJ, Wewer Albrechtsen NJ, Pedersen J, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 2014;16:1155–64
   PubMed Web of Science ®Google Scholar
• Grigoryan M, Kedees MH, Charron MJ, et al. Regulation of mouse intestinal L cell progenitors proliferation by the glucagon family of peptides. Endocrinology 2012;153:3
   Web of Science ®Google Scholar
• Salehi M, Vahl TP, D'Alessio DA. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. J Clin Endocrinol Metab 2008;93:4909–16
   PubMed Web of Science ®Google Scholar
• Deane AM, Nguyen NQ, Stevens JE, et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010;95:215–21
   PubMed Web of Science ®Google Scholar
• Vella A, Bock G, Giesler PD, et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007;56:1475–80
   PubMed Web of Science ®Google Scholar
• Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999;140:1687–94
   PubMed Web of Science ®Google Scholar
• Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342–9
   PubMed Web of Science ®Google Scholar